APPENDICES. A systematic review and economic model of the ...

Core symptoms Educational performance Quality of life Adverse events
Percentage (n) of parents reporting moderate or severe
intensity of side-effects at end of study for
MPH/placebo:
Facial tics 0% (0), 6% (1)
Tongue movements 0% (0), 0% (0)
Picking at skin 0% (0), 0% (0)
Anxious 10% (2), 6% (1)
Tired 20% (4), 11% (2)
Headache 0% (0), 6% (1)
Stomach ache 5% (1), 0% (0)
Irritable 15% (3), 11% (2)
Sad/tearful 5% (1), 0% (0)
Appetite loss 15% (3), 0% (0)
Gets wild when medication
wears off 40% (8), 44% (8)
No significant differences
Not reported Conners’ Global Index (parents),
mean and SD at baseline/3 weeks:
MPH: 2.1 (0.5) (n = 20)/1.28 (0.72)
(n = 14)
Placebo:2.2 (0.5) (n = 18)/1.54
(0.88) (n = 12)
No significant difference
IOWA
CTRS
Inattention–overactivity, mean and SD at
baseline/3 weeks:
MPH: 2.2 (0.5) (n = 20)/0.81 (0.62)
(n = 14)
Placebo: 2.2 (0.5) (n = 18)/1.49 (0.87)
(n = 12)
MPH > placebo, p < 0.05
CGI-I, mean and SD at 3 weeks (no
baseline data):
MPH: 2.35 (0.81) (n = 14)
Placebo: 3.22 (1.44) (n = 12)
MPH > placebo, p < 0.05
CGI-I: % responders (defined as
score = 2)
MPH 65%
Adderall 90%
Placebo 27%
Withdrawals (due to adverse events):
MPH: 1 subject withdrew owing to side-effects and nonresponse
Placebo: 0
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 23
Conclusions Authors’ conclusions: Both medications were superior to placebo at reducing inattentive and oppositional symptoms in the
classroom and on the CGI. Adderall produced significantly more improvements on teacher ratings and the CGI than MPH, although
the algorithm may have limited dosing in the MPH group
Reviewer’s comments: No comments noted
Study Intervention Participants Outcomes
Reference
Quinn, 2003 84 [Confidential information removed]
325